Genocea Biosciences, Inc. is a United States-based clinical-stage company that develops T cell vaccines. The Company utilizes T cell immunity to develop the next generation of vaccines. It designs vaccines using ATLAS, its technology platform. It identifies T cell antigens to induce immune responses. Its pipeline of T cell vaccines includes a clinical-stage therapeutic candidate in HSV-2, GEN-003, as well as earlier-stage programs in Pneumococcus, Chlamydia, HSV-2 prophylaxis and Malaria. Its platform develops vaccines and immunotherapies for a range of infectious diseases, cancers and autoimmune diseases.